Filing Details
- Accession Number:
- 0001415889-24-024117
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-30 20:38:12
- Reporting Period:
- 2024-09-30
- Accepted Time:
- 2024-09-30 20:38:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1506916 | A Jeffrey Meckler | C/O Travere Therapeutics, Inc. 3611 Valley Centre Dr., Suite 300 San Diego CA 92130 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-09-30 | 40,000 | $10.48 | 121,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-09-30 | 40,000 | $14.06 | 81,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Acquisiton | 2024-09-30 | 40,000 | $0.00 | 40,000 | $10.48 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2024-10-08 | No | 4 | M | Direct |
Footnotes
- This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.
- The weighted average sale price for the transaction reported was $14.0581, and the range of prices were between $13.782 and $14.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- The stock option is fully vested and exercisable.